ASTRAZENECA PHARMACEUTICALS
AZ & Me Prescription Savings Program for people with Medicare
Information last checked May 7, 2026
Contact info
- Phone
- 1-800-292-6363
- Fax
- 1-877-239-0876
- Mailing address
- 1 Medimmune WayGaithersburg, MD 20878
Eligibility
- Visit AZ&Me website to apply online or to download an application.
- Patient must meet qualifying income criteria.
- Patient must be enrolled in Medicare and are not enrolled in Limited Income Subsidy (LIS).
- NOTE: Effective May 1, 2026, the AZ&Me program will no longer accept new patients for FARXIGA and XIGDUO XR. Actively enrolled patients will continue to receive assistance for FARXIGA and XIGDUO XR until December 31, 2026
- Income limit, single
- Not published
- Income limit, couple
- Not published
- Medical expenses can be deducted
- Not published
- Social Security number asked for
- No
- US citizenship or residency required
- Yes
Not sure where your income falls? See this year's federal poverty guidelines (opens in a new tab).
Application process
- Documents to attach
- Proof of income
- Prescription
- Year-to-date prescription spend history
- Prescriber license number
- NPI number
- State license number
- Who can sign
- Physician
- Application can be faxed
- Yes
- Decision letter sent to
- Providers receive a fax, patient receives letter and phone call
Getting the medication
- Patient receives
- Medication
- Shipped to
- Provider or patient
- Supply per shipment
- Varies by product
- Time to first delivery
- 0–2 weeks
- Refills
- Refills can be requested by calling the Program
- Staying enrolled
- Enrollment is on a calendar year basis, with opportunity to re-enroll.
More from the program
Individuals can also apply online, download an application at www.azandme.com.
Medications covered
- Airsupra (albuterol/budesonide)
- Baxfendy (baxdrostat)
- Bevespi Aerosphere (glycopyrrolate and formoterol fumarate)
- Breztri Aerosphere inhalation aerosol (budesonide/glycopyrrolate/formoterol fumarate)
- Calquence (acalabrutinib)
- Fasenra (benralizumab)
- Fasenra Pen (benralizumab)
- Imfinzi (durvalumab)
- Imjudo (tremelimumab-actl)
- Lokelma (sodium zirconium cyclosilicate)